Talk to us.

A Revolution in Prostate Cancer Therapy

Avenda Health is a software and medical device company that works at the unique intersection of urology, oncology, and AI. It has developed a male lumpectomy product that treats prostate cancer while preserving the quality of life for men. Its approach aims to mitigate the 50% risk of significant complications from surgery or radiation entirely by mapping out the cancerous tumor using Artificial Intelligence (AI) and performing focal laser ablation (FLA) at the site. A urologist can perform the ablation in a clinic setting solely using local anesthesia. Avenda Health’s promise of an in-office treatment with minimal side effects is an attractive option for the hundreds of thousands of patients living with prostate cancer as well as their urologists.

 

Quick Facts for Investors

Location Santa Monica, California
VCapital Invested 2022
CEO Shyam Natarajan
Founded 2017
Founded By Brittany Berry-Pusey, Leonard Marks, Shyam Natarajan
Industry AI/ML-Enabled Medical Device

Why We Invested

Avenda Health is the only product performed in the physician office setting, using local anesthesia. It is also the only product that integrates treatment planning with therapy, resulting in maximum precision and the best quality of life outcomes. Relative to its competitors, Avenda Health is convenient, less invasive, more precise, has fewer side effects, and is highly scalable.

Avenda Health is entering the market at a time poised for a virtual cycle of growth. As prostate MRI rapidly grows (10x in the last four years), more patients are funneled to targeted biopsy to confirm the clinically significant disease. The 90% of urologists trained to perform those biopsies represent the customer base for Avenda Health’s FLA therapy, as the procedures require nearly the same technique. As Avenda Health’s FLA therapy is used more frequently and patient outcomes improve, the value of the biopsy increases, furthering the incentive to perform biopsies.

In addition to prostate cancer treatment, Avenda Health offers other promising applications. Eventually, the company aims to apply its imaging software across the entire care pathway of prostate cancer, including diagnosis, risk stratification, staging, and treatment monitoring. Today, the software platform can be used as a diagnostic aid in segmenting and targeting the biopsy, but its cancer mapping algorithm requires biopsy-confirmed prostate cancer. Eventually, Avenda Health hopes to use detailed MRI data alongside clinical data and labs to enable the software to identify clinically significant diseases without requiring a biopsy automatically.

News and Updates

June 12, 2024
AI-assisted cancer contours improve prostate tumor delineation vs SOC
June 1, 2024
Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent
May 30, 2024
AI cancer screening programs are booming, but you’ll likely have to pay for them yourself
May 22, 2024
Avenda Health Deploys AI Cancer Imaging Technology at Kasraeian Urology, Improving Local Access to Cutting Edge Prostate Cancer Care
May 8, 2024
New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods
April 10, 2024
Improve Treatment Margins with the Fusion Bx and Unfold AI
March 22, 2024
Avenda Health Introduces Unfold AI | Revolutionizing Prostate Cancer Care
March 7, 2024
Unfold AI demonstrates utility for prostate cancer treatment planning in real-world case
November 1, 2023
AMA Will Issue New CPT Code for AI Prostate Cancer Mapping Tool
September 14, 2023
Artificial Intelligence May Improve Detection, Prostate Cancer Decision Making
August 8, 2023
Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence
June 21, 2023
Avenda Health Uses AI for Better Health Care Decisions
June 20, 2023
Avenda Health Featured on NBC News During President Biden’s AI Forum in SF
June 15, 2023
Unfold AI Find a Doctor Research Publications Company Contact Us Stanford Research Study Provides Further Evidence for Avenda Health’s Personalized Prostate Cancer Mapping Using Machine Learning
April 25, 2023
Avenda Health Announces First Commercial Use of Unfold AI on Prostate Cancer Patients in the U.S.
April 19, 2023
Avenda Health Partners with BioscienceLA to Establish New Life Sciences Innovation Hub in U.S.
March 15, 2023
Avenda Health’s Brit Berry-Pusey uses AI for prostate cancer
December 13, 2022
First AI-Powered Precision Oncology Platform for Prostate Cancer Care, iQuestTM, Receives FDA Clearance
December 11, 2022
Avenda’s Platform for Personalized Prostate Cancer Mapping Earns FDA Clearance
December 7, 2022
Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?
December 7, 2022
First AI-Powered Precision Oncology Platform for Prostate Cancer Care, iQuestTM, Receives FDA Clearance
May 12, 2021
Avenda Health Granted FDA Breakthrough Device Designation for Technology to Treat Prostate Cancer